The guidance raise signals improved confidence in Pharma Direct and subscription momentum, but the steep decline in prescription transactions (24%) and GAAP EPS miss are concerning. Watch for continued MAC erosion and whether Pharma Direct growth can offset core weakness.
Price Chart
Executive Summary
GoodRx reported Q1 2026 revenue of $194.0M (-4% YoY), GAAP EPS of $0.00 (miss vs $0.03 consensus), and adjusted EBITDA of $58.3M (-16.5% YoY). Pharma Direct revenue surged 82% YoY and subscription revenue grew 16%, but the core prescription transactions business declined 24%. Management raised full-year 2026 revenue and adjusted EBITDA guidance.
Key Financial Metrics
Key Facts
- Revenue $194.0M, down 4% YoY from $203.0M
- GAAP EPS $0.00, missed consensus of $0.03
- Adjusted EBITDA $58.3M, down 16.5% YoY
- Pharma Direct revenue +82% YoY to $52.2M
- Subscription revenue +16% YoY to $24.4M
- Prescription transactions revenue -24% YoY to $113.7M
- Full-year 2026 revenue guidance raised to $765-$785M (from $750-$780M)
- Full-year 2026 adjusted EBITDA guidance raised to $235M (from $230M)
Financial Impact
Revenue decline of $9M YoY; adjusted EBITDA decline of $11.5M; GAAP net income down $9.9M vs prior year quarter
Risk Factors
- Ongoing retail pharmacy store closures pressuring prescription transaction volumes
- TrumpRx.gov government platform could further disrupt the business
- GAAP EPS near zero with significant stock-based compensation
- Debt of $493.8M vs market cap of $867M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001809519-26-000110 |
| Document: gdrx-20260506.htm | 0001809519-26-000110 |
| Document: 0001809519-26-000110-index-headers.html | 0001809519-26-000110 |
| Document: 0001809519-26-000110-index.html | 0001809519-26-000110 |
| Document: 0001809519-26-000110.txt | 0001809519-26-000110 |
| 8-K Data (Synthetic) | 0001809519-26-000110 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $3.44 $3.52 | ▲ +2.33% | ▲ +2.89% | $3.48 (+1.16%) |
Aug 19, 2026 9w ago | 144 | $3.54 $3.40 | ▲ +3.95% | ▲ +2.00% | $3.48 (+1.69%) |
May 6, 2026 24w ago | 8-K | $2.84 $2.81 | ▼ −1.06% | ▼ −4.19% | $3.48 (+22.54%) |
Apr 24, 2026 26w ago | 8-K | $2.28 $2.78 | ▲ +21.93% | ▲ +16.97% | $3.48 (+52.63%) |
Apr 3, 2026 29w ago | 8-K | $2.07 $2.50 | ▲ +20.77% | ▲ +11.79% | $3.48 (+68.12%) |
Feb 25, 2026 34w ago | 8-K | $1.99 $2.04 | ▼ −2.51% | ▼ −8.91% | $3.48 (−74.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers